Abstract
Postoperative low cardiac output syndrome has been shown to have both a central and a peripheral vascular involvement. Therefore, inodilators which provide with a combination of positive inotropic and vasodilating therapy, conceptually should be an ideal form of treatment. However, contradictory data on these drugs exist. Phosphodiesterase inhibitors (e.g. milrinone) and more recently calcium sensitizers (e.g. levosimendan) have been most commonly used groups in the clinical setting. This review will summarize the pharmacology of inodilators with a special foccus on current clinical evidence. This article addresses the sixth of eight topics comprising the special issue entitled “Pharmacologic strategies with afterload reduction in low cardiac output syndrome after pediatric cardiac surgery”.
Keywords: Cardiac output syndrome, inodilators, levosimendan, milrinone, pediatric cardiac surgery, pharmacology.
Graphical Abstract
Current Vascular Pharmacology
Title:Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Volume: 14 Issue: 1
Author(s): Angela Ferrer-Barba, Iria Gonzalez-Rivera and Victor Bautista-Hernandez
Affiliation:
Keywords: Cardiac output syndrome, inodilators, levosimendan, milrinone, pediatric cardiac surgery, pharmacology.
Abstract: Postoperative low cardiac output syndrome has been shown to have both a central and a peripheral vascular involvement. Therefore, inodilators which provide with a combination of positive inotropic and vasodilating therapy, conceptually should be an ideal form of treatment. However, contradictory data on these drugs exist. Phosphodiesterase inhibitors (e.g. milrinone) and more recently calcium sensitizers (e.g. levosimendan) have been most commonly used groups in the clinical setting. This review will summarize the pharmacology of inodilators with a special foccus on current clinical evidence. This article addresses the sixth of eight topics comprising the special issue entitled “Pharmacologic strategies with afterload reduction in low cardiac output syndrome after pediatric cardiac surgery”.
Export Options
About this article
Cite this article as:
Ferrer-Barba Angela, Gonzalez-Rivera Iria and Bautista-Hernandez Victor, Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery, Current Vascular Pharmacology 2016; 14 (1) . https://dx.doi.org/10.2174/1570161113666151014125314
DOI https://dx.doi.org/10.2174/1570161113666151014125314 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: New Developments in the Treatment and Prevention of Vascular Disease - Part 1 (Executive Editors: N. Katsiki, V.G. Athyros and D.P. Mikhailidis)]
Current Pharmaceutical Design Support and Social Contact as a Decisive Meta-Variable in Morbidity and Social Welfare of the Older Person
Current Aging Science MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Standardization of QRS Duration Measurement and LBBB Criteria in CRT Trials and Clinical Practice
Current Cardiology Reviews The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis
Current Vascular Pharmacology Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Endothelial Dysfunction, Oxidative Stress and Inflammation in Atherosclerosis: Beneficial Effects of Statins
Current Medicinal Chemistry Cardioprotective Role of <i>Theobroma cacao</i> against Isoproterenol-Induced Acute Myocardial Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry The sdLDL Reduces MRC1 Expression Level and Secretion of Histamin e in Differentiated M2-macrophages from Patients with Coronary Artery Stenosis
Cardiovascular & Hematological Disorders-Drug Targets A Study of Metabolic Parameters in Patients with Gout: A Single Center Study from Nepal
Endocrine, Metabolic & Immune Disorders - Drug Targets Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Current Pharmaceutical Design Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design New Class of Pyrimidinesulfamoyl Containing Pyrazole and Pyrrole Derivatives and Their Antioxidant Activity
Letters in Organic Chemistry Preface [Hot Topic: Recent Progress in Cardiovascular Gene Therapy;Emerging to Real Drug? (Guest Editor: Ryuichi Morishita)]
Current Gene Therapy Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
Current Pharmaceutical Design